Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antiplatelet Therapy for Chronic Recalcitrant Urticaria
NCT06268470Phase 2Active, not recruiting
- Sponsor
- Chulalongkorn University
- Start
- Jun 2018
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of cilostazol and dipyridamole in chronic spontaneous urticaria (CSU) (2 arms), sponsored by Chulalongkorn University. Primary endpoint: Weekly Urticaria Activity Score at 4 weeks. Started Jun 2018; status: active, not recruiting.
02
Drugs
cilostazoldipyridamole
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT06268470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06268470.